August 12, 2020 Contingent value is back in vogue This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
July 27, 2020 Curevac muddies the Moderna/Arbutus waters further The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.
March 31, 2020 Amarin falls at obvious hurdle Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.